3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Breast Neoplasms
19
Triple Negative Breast Neoplasms
15
Carcinoma, Non-Small-Cell Lung
6
Lung Neoplasms
4
Carcinoma, Transitional Cell
4
Urinary Bladder Neoplasms
3
Neoplasm Metastasis
3
Brain Neoplasms
3
Salivary Gland Neoplasms
2
Uterine Cervical Neoplasms
1
Urothelial Bladder Carcinoma
1
Thyroid Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumor
1
Small Cell Lung Carcinoma
1
Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma
1
Recurrence
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Oropharyngeal Neoplasms
1
Neoplasms
1
Neoplasm, Residual
1
Mouth Neoplasms
1
Metastatic Urothelial Cancer
1
Laryngeal Neoplasms
1
Klatskin Tumor
1
Hypopharyngeal Neoplasms
1
HER2-negative Breast Cancer
1
Glioblastoma
1
Interventions
enfortumab vedotin
2
Gemcitabine
2
Carboplatin
2
zimberelimab
1
sacituzumab govitecan
1
pembrolizumab
1
olaparib
1
avelumab
1
Oxaliplatin
1
Nivolumab
1
Cisplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Metastatic Urothelial Cancer
×
sacituzumab govitecan
×
Clear all
NCT03547973
2026-03-16
TROPHY U-01
Gilead Sciences
Phase 2
Recruiting
827 enrolled
1 FDA